A61P 37 - Drugs for immunological or allergic disorders

Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2002
10/24/2002	US20020156013 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
10/24/2002	US20020156000 Inhibiting NF-kappa B-dependent target gene expression in a cell.
10/24/2002	US20020155997 Biologically active material isolated from non-pathogenic bacteria, such as Enterobacteriaceae
10/24/2002	US20020155609 Monocyte-specific particulate delivery vehicle
10/24/2002	US20020155604 Compositions and methods for regulating lymphocyte activation
10/24/2002	US20020155597 In vivo production and delivery of erthropoietin or insulinotropin for gene therapy
10/24/2002	US20020155534 SBHWSB2: a new member of the WD40 SOCS box family
10/24/2002	US20020155528 Regulation of human CysLT2-like GPCR protein
10/24/2002	US20020155510 Dendritic cell-specific antibodies
10/24/2002	US20020155432 Genetically engineered herpes virus for the treatment of cardiovascular disease
10/24/2002	US20020155127 Genetic vaccine against human immunodeficiency virus
10/24/2002	US20020155126 Pharmacological composition containing yeast cell wall fraction
10/24/2002	US20020155115 Cancer therapy
10/24/2002	US20020155111 For the vaccination of patients having malignant B cell diseases
10/24/2002	US20020155110 Soluble mast cell function associated antigen (MAFA) pharmaceutical compositions and methods of making and using them
10/24/2002	US20020155107 Methods and formulations for reducing circulating antibodies
10/24/2002	DE10119905A1 Enriching intermediates in the mevalonate-independent pathway of isoprenoid synthesis, useful for therapeutic activation of T cells, comprises altering enzymatic activity in the pathway
10/24/2002	CA2490819A1 Compounds useful as anti-inflammatory agents
10/24/2002	CA2444761A1 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
10/24/2002	CA2444632A1 Vascular endothelial growth factor 2
10/24/2002	CA2444465A1 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
10/24/2002	CA2444247A1 Inhibitors of integrin .alpha.v.beta.6
10/24/2002	CA2444164A1 Pufa polyketide synthase systems and uses thereof
10/24/2002	CA2444133A1 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
10/24/2002	CA2443903A1 Antibodies to vla-1
10/24/2002	CA2443897A1 Transporters and ion channels
10/24/2002	CA2443874A1 Intermediates and enzymes of the non-mevalonate isoprenoid pathway
10/24/2002	CA2443777A1 Therapeutic and diagnostic uses of antibody specificity profiles
10/24/2002	CA2443709A1 Novel cyclo azaphospha hydrocarbons
10/24/2002	CA2443697A1 1,4-disubstituted benzo-fused compounds
10/24/2002	CA2443487A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	CA2443468A1 Pharmaceutical product with reticulated crystalline microstructure
10/24/2002	CA2443408A1 Kinases and phosphatases
10/24/2002	CA2443244A1 Enzymes
10/24/2002	CA2443234A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	CA2442953A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation
10/24/2002	CA2442729A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/24/2002	CA2441699A1 Methods and compositions for stable transgenic plant pharmaceuticals and their use as contraceptives
10/24/2002	CA2440842A1 Novel 1h-indazole compounds
10/24/2002	CA2438107A1 G-protein coupled receptor molecules and uses thereof
10/24/2002	CA2431553A1 Cxcr3 antagonists
10/23/2002	EP1251177A2 Cytokine-, stress-, and oncoprotein-activited human protein kinase kinases
10/23/2002	EP1250849A1 Morinda citrifolia (Noni) enhanced animal food product
10/23/2002	EP1250443A2 ANTI-CD3 SINGLE-CHAIN ANTIBODIES HAVING HUMAN C $g(m)?3 AND C $g(m)?4 DOMAINS
10/23/2002	EP1250432A2 Nuclear hormone receptors
10/23/2002	EP1250422A2 Myeloid colony stimulating factor and uses thereof
10/23/2002	EP1250421A1 Recombinant flaviviruses and methods of use thereof
10/23/2002	EP1250358A1 Therapeutic peptides
10/23/2002	EP1250354A1 Peptide fragments of colostrinin and their use
10/23/2002	EP1250348A1 Antisense modulation of daxx expression
10/23/2002	EP1250331A1 Formulation for protection against oxidative stress containing benzofuranone derivatives
10/23/2002	EP1250317A2 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments
10/23/2002	EP1250157A1 Antisense modulation of inducible nitric oxide synthase expression
10/23/2002	EP1250155A1 Angiogenesis and vascular permeability modulators and inhibitors
10/23/2002	EP1250154A2 G-csf conjugates
10/23/2002	EP1250142A1 Multivalent electron active compositions and methods of making and using same
10/23/2002	EP1250137A2 Jak/stat pathway inhibitors and the uses thereof
10/23/2002	EP1250135A1 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
10/23/2002	EP1250133A1 Ophthalmic anti-allergy compositions suitable for use with contact lenses
10/23/2002	EP1250116A1 Pharmaceutical and cosmetic carrier or composition for topical application
10/23/2002	EP1250055A1 Immune modulation with death receptor-induced apoptosis
10/23/2002	EP1063891A4 Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
10/23/2002	EP0925303B1 Phosphinic acid amides as matrix metalloprotease inhibitors
10/23/2002	EP0883681B1 Conjugated linoleic acids for attenuating the allergic response
10/23/2002	EP0858345B1 Use of muteins of wild-type cytokines as immunogens
10/23/2002	EP0826000B1 Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
10/23/2002	EP0783499B1 Benzofuran derivatives as tachykinin antagonists
10/23/2002	EP0766745B1 Monoclonal antibody specific for human 4-1bb and cell line producing same
10/23/2002	EP0723552B1 Oligopeptides derived from c-reactive protein fragments
10/23/2002	CN1376165A Materials and methods for inhibition of Lg E production
10/23/2002	CN1376163A Highly purified cytokine activating factor and methods of use
10/23/2002	CN1376157A Triazolopurine derivatives, drug compositions containing the same and adenosine A3 receptor affinitive agents
10/23/2002	CN1376156A Benzodiazepin derivatives, the production and use thereof
10/23/2002	CN1376146A Solid-state form of celecoxil having enhanced bioavailability
10/23/2002	CN1376144A Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
10/23/2002	CN1376073A Method of expressing antigen on the surface of an antigen-presenting cell by photochemical internalisation
10/23/2002	CN1376068A Echinacea supplement and method of manufacture
10/23/2002	CN1376065A Compositions having improved stability
10/23/2002	CN1376063A Cyclic amine CCR3 antagonisis
10/23/2002	CN1375500A Thymic peptide fusion protein as one new interferon and its prepn. and use
10/23/2002	CN1375314A Fermented soybean extracted liquid and composite medicine containing the said liquid
10/23/2002	CN1375289A Ampelosis general flavone composition with liver protecting function
10/23/2002	CN1093125C Sulfamide-metalloprotease inhibitors
10/23/2002	CN1092960C Pharmaceutical composition comprising proteinase inhibitor and monoglyceride
10/22/2002	US6469174 Substituted pyrrolobenzimidazoles for treating inflammatory diseases
10/22/2002	US6469162 Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy and diagnosis
10/22/2002	US6469137 Myelopeptides and their therapeutic use
10/22/2002	US6469055 Modulating expression, production, or formation of amyloid precursor protein by administering a nonsteroidal antiinflammatory agent that is a cyclooxygenase inhibitor
10/22/2002	US6469054 Aryl sulphonamides and analogues
10/22/2002	US6469047 Tyrosine derivatives
10/22/2002	US6469045 Thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products; oral administration
10/22/2002	US6469036 Peptidyl heterocyclic ketones useful as tryptase inhibitors
10/22/2002	US6469032 3-(4′-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
10/22/2002	US6469025 For the prophylaxis or treatment of a disease or disorder in a mammal in which the extravasation of leukocytes plays a role; inhibiting the binding of alpha 4 integrins to their ligands
10/22/2002	US6469024 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
10/22/2002	US6469020 Hydroxamic and carboxylic acid derivatives
10/22/2002	US6469018 Compounds
10/22/2002	US6469013 Therapeutic compounds
10/22/2002	US6469004 Benzoheterocycles and their uses as MEK inhibitors
10/22/2002	US6468964 Administering to human or animal active agent capable of preventing or controlling acid and endotoxin accumulation in gastrointestinal tract, selected from antibiotics, enzymes, clays, probiotics, compounds which slow rate of passage

1 ... 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 ... 1172